Sign in
JNJ-JOHNSON & JOHNSON
Johnson & Johnson Sues Samsung Bioepis Over Biosimilar Launch Amidst Competitive Pressure and Ongoing Focus on Innovation and Growth
Member Only Article
Thursday
27 February, 2025
Johnson & Johnson is facing a pivotal moment as it battles Samsung Bioepis over the launch of a biosimilar for its blockbuster drug Stelara, amidst a backdrop of fierce competition and recent setbacks in its vaccine trials. Can J&J maintain its status as a Dividend King while navigating these turbulent waters?
Article Impact Score
0
50
100
Underperform
Bearish
Neutral
Bullish
Outperform
0
Key Takeaways
- Loading...
Most Read
Join Foliko Premium!
Unlock the entire library of Foliko's Generative AI Investment Research. Plus, get AI powered trading signals and stock price predictions.
Go Premium - 7 Day Free Trial